M G Butler1, B K Smith, J Lee, C Gibson, C Schmoll, W V Moore, J E Donnelly. 1. Department of Psychiatry & Behavioral Sciences, University of Kansas Medical Center, and Department of Pediatrics, Children's Mercy Hospital, Kansas City, United States. mbutler4@kumc.edu
Abstract
OBJECTIVE: Since limited data exist on adults with Prader-Willi syndrome (PWS) and growth hormone (GH) treatment, we report our experience on the effects of treatment for one year on body composition, physical activity, strength and energy expenditure, diet, general chemistry and endocrine data with quality of life measures. DESIGN: We studied 11 adults with PWS (6F:5M; average age=32 yrs) over a 2 year period with GH treatment during the first year only. Electrolytes, IGF-I, glucose, thyroid, insulin, lipids, body composition, physical activity and strength, diet, energy expenditure and quality of life data were collected and analyzed statistically using linear modeling at baseline, at 12 months following GH therapy and at 24 months after treatment cessation for 12 months. RESULTS: Total lean muscle mass was significantly increased (p<0.05) during GH treatment along with moderate-vigorous physical activity and plasma IGF-I and HDL levels, but returned to near baseline after treatment. Percent body fat decreased during the 12 months of GH treatment but increased after treatment. CONCLUSIONS: Previously reported beneficial effects of GH treatment in children with PWS were found in our adults regarding body composition, physical activity and plasma HDL and IGF-I levels. Several beneficial effects diminished to near baseline after cessation of GH treatment for 12 months supporting the continuation of treatment in PWS into adulthood and possibly adults not previously treated during childhood.
OBJECTIVE: Since limited data exist on adults with Prader-Willi syndrome (PWS) and growth hormone (GH) treatment, we report our experience on the effects of treatment for one year on body composition, physical activity, strength and energy expenditure, diet, general chemistry and endocrine data with quality of life measures. DESIGN: We studied 11 adults with PWS (6F:5M; average age=32 yrs) over a 2 year period with GH treatment during the first year only. Electrolytes, IGF-I, glucose, thyroid, insulin, lipids, body composition, physical activity and strength, diet, energy expenditure and quality of life data were collected and analyzed statistically using linear modeling at baseline, at 12 months following GH therapy and at 24 months after treatment cessation for 12 months. RESULTS: Total lean muscle mass was significantly increased (p<0.05) during GH treatment along with moderate-vigorous physical activity and plasma IGF-I and HDL levels, but returned to near baseline after treatment. Percent body fat decreased during the 12 months of GH treatment but increased after treatment. CONCLUSIONS: Previously reported beneficial effects of GH treatment in children with PWS were found in our adults regarding body composition, physical activity and plasma HDL and IGF-I levels. Several beneficial effects diminished to near baseline after cessation of GH treatment for 12 months supporting the continuation of treatment in PWS into adulthood and possibly adults not previously treated during childhood.
Authors: Elbrich P C Siemensma; Roderick F A Tummers-de Lind van Wijngaarden; Dederieke A M Festen; Zyrhea C E Troeman; A A E M Janielle van Alfen-van der Velden; Barto J Otten; Joost Rotteveel; Roelof J H Odink; G C B Karen Bindels-de Heus; Mariette van Leeuwen; Danny A J P Haring; Wilma Oostdijk; Gianni Bocca; E C A Mieke Houdijk; A S Paul van Trotsenburg; J J Gera Hoorweg-Nijman; Hester van Wieringen; René C F M Vreuls; Petr E Jira; Eelco J Schroor; Evelyn van Pinxteren-Nagler; Jan Willem Pilon; L Bert Lunshof; Anita C S Hokken-Koelega Journal: J Clin Endocrinol Metab Date: 2012-04-16 Impact factor: 5.958
Authors: Andrea M Haqq; Diane D Stadler; Russell H Jackson; Ron G Rosenfeld; Jonathan Q Purnell; Stephen H LaFranchi Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958
Authors: Richard P Troiano; David Berrigan; Kevin W Dodd; Louise C Mâsse; Timothy Tilert; Margaret McDowell Journal: Med Sci Sports Exerc Date: 2008-01 Impact factor: 5.411
Authors: Harriette R Mogul; Phillip D K Lee; Barbara Y Whitman; William B Zipf; Michael Frey; Susan Myers; Mindy Cahan; Belinda Pinyerd; A Louis Southren Journal: J Clin Endocrinol Metab Date: 2008-01-22 Impact factor: 5.958
Authors: Erik P Kirk; Joseph E Donnelly; Bryan K Smith; Jeff Honas; James D Lecheminant; Bruce W Bailey; Dennis J Jacobsen; Richard A Washburn Journal: Med Sci Sports Exerc Date: 2009-05 Impact factor: 5.411
Authors: Merlin G Butler; Jaehoon Lee; Ann M Manzardo; June-Anne Gold; Jennifer L Miller; Virginia Kimonis; Daniel J Driscoll Journal: Pediatrics Date: 2014-12-08 Impact factor: 7.124
Authors: Merlin G Butler; Jaehoon Lee; Devin M Cox; Ann M Manzardo; June-Anne Gold; Jennifer L Miller; Elizabeth Roof; Elisabeth Dykens; Virginia Kimonis; Daniel J Driscoll Journal: Clin Pediatr (Phila) Date: 2016-02-03 Impact factor: 1.168
Authors: Ranim Mahmoud; Anna Leonenko; Merlin G Butler; Pamela Flodman; June-Anne Gold; Jennifer L Miller; Elizabeth Roof; Elisabeth Dykens; Daniel J Driscoll; Virginia Kimonis Journal: Clin Genet Date: 2021-03-13 Impact factor: 4.296